Lamia Berrada: The Architect of Pharmaceutical Growth in Morocco

Friday 03 May 2024 - 14:18

In the dynamic landscape of Morocco's pharmaceutical industry, one prominent figure stands out for her bold vision and unwavering leadership. Lamia Berrada, chairwoman of the board at Bottu Group, has elevated the family business to become the second-largest pharmaceutical company in the country, achieving an impressive consolidated revenue of 2.4 billion dirhams.

A graduate in dental surgery from Paris Descartes University, this exceptional woman initially worked independently in the United States, managing two dental practices with great success before joining the family business as a Business Development Manager. It was in 2007 when she took the helm at Bottu, injecting new life into the company and setting it on a trajectory of significant growth.

Under her visionary leadership, Bottu has experienced remarkable expansion, now operating in 24 countries across Africa and the Middle East. Among its portfolio of 300 specialties, Doliprane, the iconic analgesic, holds a place of honor, with 32.1 million boxes sold in pharmacies in 2023, making it the best-selling medication in Morocco.

An Ambitious Investment Strategy

Bottu's ascent is rooted in a bold investment policy. In 2022, the inauguration of its new headquarters and industrial unit allowed the company to increase its production capacity to over 100 million units. The following year, the strategic acquisition of BioXpert broadened its product portfolio, opening new avenues for growth.

Alongside its flagship, four subsidiaries make up the Bottu Group ecosystem: Bottu International (export development), Sophanord (wholesale distribution of medicines and pharmaceutical products), Althea (women's health specialties), and BioXpert (dietary supplements).

Strategic Partnerships and Operational Excellence

The Bottu Group has forged strategic partnerships with major global players in the pharmaceutical industry to meet the health needs of a diverse population facing various health risks. Involved at every level of the pharmaceutical value chain, from development to distribution, Bottu holds an impressive array of certifications, from ISO 9001 to ISO 45001, ensuring its products meet the most stringent industry standards.

Social Responsibility and Philanthropic Commitment

Beyond her business achievements, Lamia Berrada is deeply committed to societal engagement. She closely monitors the activities of the Azzadine Berrada Foundation, the philanthropic organization founded by her father, which operates in remote regions of the country, supporting rural schools, healthcare centers, and collaborating with humanitarian NGOs. This Corporate Social Responsibility (CSR) effort is a source of great pride for the Bottu family.

Lamia Berrada embodies the spirit of a visionary leader, combining commercial success with societal responsibility, shaping the future of Morocco's pharmaceutical industry with determination and foresight.